@article{mbs:/content/journal/jgv/10.1099/0022-1317-75-6-1339, author = "Fujii, Hiroyuki and Takita-Sonoda, Yoshiko and Mifune, Kumato and Hirai, Kazuhiro and Nishizono, Akira and Mannen, Kazuaki", title = "Protective efficacy in mice of post-exposure vaccination with vaccinia virus recombinant expressing either rabies virus glycoprotein or nucleoprotein", journal= "Journal of General Virology", year = "1994", volume = "75", number = "6", pages = "1339-1344", doi = "https://doi.org/10.1099/0022-1317-75-6-1339", url = "https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-75-6-1339", publisher = "Microbiology Society", issn = "1465-2099", type = "Journal Article", abstract = "Mice vaccinated intraperitoneally (i.p.) with 107 p.f.u. of a vaccinia virus recombinant expressing either the glycoprotein (rVac-G) or nucleoprotein (rVac-N) of rabies virus 3 weeks before challenge were protected against peripheral lethal infection. Similarly, by postexposure vaccination in which mice were first infected with rabies virus and subsequently vaccinated i.p. with the recombinant, rVac-G conferred protection when given immediately following infection and up to 24 h after infection. Prior treatment of those mice with anti-CD8 monoclonal antibodies (MAb) did not significantly affect the outcome of the infection. In contrast, rVac-N failed to confer protection even with higher doses (108 p.f.u.) of the virus or even when administered by the intradermal route. Anti-nucleoprotein antibody production by these mice was not suppressed by prior rabies virus infection and the levels and the time of antibody production were similar to those of anti-glycoprotein antibody production in mice vaccinated with rVac-G after rabies virus infection. The cytotoxic T lymphocyte response was also not down-regulated by rabies virus in the mice that were given rVac-N. Possible mechanism(s) for the ineffectiveness of rVac-N by post-exposure vaccination in contrast to pre-exposure vaccination was discussed.", }